February 23, 2005
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
Inspire revenues top $11 million in 2004
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
DURHAM, N.C. — Inspire Pharmaceuticals reported revenues of $11.1 million for 2004, compared with $5.2 million for the previous year. The company attributed the increase to revenues from sales of two drugs it co-promotes with Allergan.
Both drugs were on the U.S. market for less than the full year, the company noted in a press release. The allergic conjunctivitis medication Elestat (epinastine) has been on the U.S. market for 11 months, while the dry eye drug Restasis (cyclosporine) has been marketed for nine.
According to Inspire, Elestat held an 8% share of the market as of early February 2005.
Inspire predicted it will earn co-promotion revenue in the range of $17 to $20 million for 2005.